Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $21.83 Average PT from Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have been given an average rating of “Moderate Buy” by the eight brokerages that are currently covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating, two have given a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $21.8333.

Several equities research analysts recently weighed in on TBPH shares. HC Wainwright increased their price target on Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. BTIG Research reissued a “buy” rating and issued a $21.00 target price on shares of Theravance Biopharma in a report on Friday, March 20th. Zacks Research raised Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a report on Thursday, March 19th. Wall Street Zen raised Theravance Biopharma from a “buy” rating to a “strong-buy” rating in a report on Tuesday, April 14th. Finally, TD Cowen raised their target price on Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a report on Monday, March 23rd.

Theravance Biopharma Trading Up 2.1%

Shares of TBPH opened at $16.81 on Friday. The firm has a market cap of $865.55 million, a PE ratio of 8.28 and a beta of 0.17. The company’s 50 day simple moving average is $16.08 and its 200-day simple moving average is $17.26. Theravance Biopharma has a 12-month low of $8.33 and a 12-month high of $21.03.

Insider Buying and Selling

In other news, SVP Rhonda Farnum sold 31,067 shares of Theravance Biopharma stock in a transaction on Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the completion of the transaction, the senior vice president owned 232,699 shares of the company’s stock, valued at $3,248,478.04. The trade was a 11.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in TBPH. Baader Bank Aktiengesellschaft purchased a new stake in Theravance Biopharma during the 3rd quarter worth about $781,000. JPMorgan Chase & Co. increased its position in Theravance Biopharma by 78.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 213,104 shares of the biopharmaceutical company’s stock worth $3,111,000 after purchasing an additional 93,591 shares in the last quarter. Hillsdale Investment Management Inc. purchased a new stake in Theravance Biopharma during the 3rd quarter worth about $4,536,000. Inspire Investing LLC purchased a new stake in Theravance Biopharma during the 3rd quarter worth about $1,074,000. Finally, WINTON GROUP Ltd purchased a new stake in Theravance Biopharma during the 3rd quarter worth about $1,118,000. Institutional investors and hedge funds own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.